Details of the Drug Combinations

General Information of This Drug (ID: DMWBZJD)

Drug Name
GDC-0068   DMWBZJD
Synonyms RG7440
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 3 [1]
Colorectal cancer 2B91.Z Phase 3 [1]
Prostate cancer 2C82.0 Phase 3 [2]
Gastric adenocarcinoma 2B72 Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

6 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
GDC-0068 + Trametinib DCC2IXN Trametinib Embryonal rhabdomyosarcoma (Cell Line: Rh36) [5]
GDC-0068 + Trametinib DCOGK5V Trametinib Embryonal rhabdomyosarcoma (Cell Line: CTR) [5]
GDC-0068 + Trametinib DC8N0RG Trametinib Embryonal rhabdomyosarcoma (Cell Line: RD) [5]
GDC-0068 + Cotellic DCUJIAF Cotellic Embryonal rhabdomyosarcoma (Cell Line: Rh36) [5]
GDC-0068 + Cotellic DCVNHGU Cotellic Embryonal rhabdomyosarcoma (Cell Line: CTR) [5]
GDC-0068 + Cotellic DC7FFBO Cotellic Embryonal rhabdomyosarcoma (Cell Line: RD) [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DrugCom(s)
5 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Cotellic + GDC-0068 DC5EVDK Cotellic Neoplasms [6]
Fulvestrant + GDC-0068 DCSUCHX Fulvestrant Breast Cancer [7]
Letrozole + GDC-0068 DCCTZ36 Letrozole Breast Cancer [7]
Capecitabine + GDC-0068 DCEW2GK Capecitabine Triple Negative Breast Cancer [8]
Eribulin + GDC-0068 DCO7S95 Eribulin Triple Negative Breast Cancer [8]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of Roche.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031868)
5 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6 ClinicalTrials.gov (NCT01562275) A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors
7 ClinicalTrials.gov (NCT03959891) AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
8 ClinicalTrials.gov (NCT04464174) Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer